Search clinical trials for: Placebo to Aliskiren

Total 60388 results

Novartis Pharmaceuticals

Completed

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Hypertension

United States, Taiwan, Italy, Slovakia, Canada, Spain, Puerto Rico
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

Heart Failure

Germany, Lithuania
Novartis

Completed

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus (ViVID)

Hypertension

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Novartis

Completed

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Hypertension

Hungary, Poland, United States, Belgium, Brazil
Jichi Medical University

Completed

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

Hypertension | Chronic Kidney Disease

Japan
John H. Stroger Hospital

Terminated

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Diabetes | Proteinuria | Albuminuria | Microalbuminuria | Macroalbuminuric Diabetic Nephropathy

United States
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

Hypertension, Diabetes Mellitus

United States, Germany
Novartis

Completed

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Essential Hypertension

Switzerland, Germany
Novartis

Completed

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Hypertension

United States, Germany
Kagawa University

Unknown

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Hypertension | Glomerulonephritis, IGA

Japan
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Hypertension

United States, Germany
Novartis

Completed

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Diabetes Type 2

Denmark
Chulalongkorn University

Unknown

The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Peritoneal Membrane Failure

Thailand
Novartis Pharmaceuticals

Completed

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | High Blood Pressure

United States
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Novartis

Completed

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

Hypertension

Germany, United States
Novartis

Terminated

Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

Hypertension | Abdominal Obesity

Germany
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Novartis

Completed

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

Hypertension | Diabetes

Switzerland, Sweden, Romania, Belgium, Spain, United States, Ukraine
Novartis

Completed

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Hypertension

United States
Novartis

Completed

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Hypertension

United States, Belgium, Canada, Germany, Italy, Netherlands, Peru, Russian Federation, Switzerland, United Kingdom
Novartis

Completed

A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

Hypertension

Switzerland
Novartis

Completed

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Germany
Novartis

Completed

A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension

Hypertension

Switzerland, Spain, Hungary, Germany
Novartis

Completed

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Hypertension

United States, Germany
Novartis

Completed

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Hypertension

United States, Germany
Novartis

Completed

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

Hypertension

Japan
Novartis

Completed

Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Hypertension

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Diabetic Nephropathy

United States, Germany, Netherlands, Russian Federation, United Kingdom, Romania, Spain, France, Italy, Greece, Canada, Denmark
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Novartis Pharmaceuticals

Terminated

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (APOLLO)

Cardiovascular Events

Colombia, India, South Africa, Canada, Spain, Hungary, United States, Germany, Ireland, Argentina, Philippines, Brazil, Sweden, Malaysia, Chile, Israel, Czech Republic, Netherlands
The University of Hong Kong
Queen Mary Hospital, Hong Kong; United Christian Hospital

Completed

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

IgA Nephropathy

China
Novartis

Completed

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine

Hypertension

Switzerland, Germany
UMC Utrecht

Unknown

Aliskiren and Muscle Sympathetic Nerve Activity (MSNA)

Hypertension | Chronic Kidney Disease | Muscle Sympathetic Nerve Activity

Netherlands
Lerdsin General Hospital

Unknown

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Type 2 Diabetes With Nephropathy

Thailand
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

Hypertension

Germany, United States
Novartis

Completed

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)

High Blood Pressure

Venezuela
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Meir Medical Center
Novartis Pharmaceuticals

Terminated

Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements (REALITY)

Blood Pressure, High

Israel
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Novartis

Completed

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

Hypertension

United States, Germany
Novartis

Completed

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

Hypertension

Germany, United States
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria

3

Subscribe